| Chloroquine triggers cell death and inhibits PARPs in cell models of aggressive hepatoblastoma K Eloranta, S Cairo, E Liljeström, T Soini, A Kyrönlahti, JG Judde, ... Frontiers in oncology 10, 1138, 2020 | 19 | 2020 |
| Transcription factor GATA4 associates with mesenchymal-like gene expression in human hepatoblastoma cells T Soini, K Eloranta, M Pihlajoki, A Kyrönlahti, O Akinrinade, N Andersson, ... Tumor Biology 40 (7), 1010428318785498, 2018 | 16 | 2018 |
| SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration K Eloranta, M Pihlajoki, E Liljeström, R Nousiainen, T Soini, J Lohi, ... Frontiers in oncology 13, 1118268, 2023 | 9 | 2023 |
| Liver secretin receptor predicts portoenterostomy outcomes and liver injury in biliary atresia N Godbole, I Nyholm, M Hukkinen, JR Davidson, A Tyraskis, J Lohi, ... Scientific Reports 12 (1), 7233, 2022 | 5 | 2022 |
| Analysis of non-relapsed and relapsed adult type granulosa cell tumors suggests stable transcriptomes during tumor progression N Andersson, UM Haltia, A Färkkilä, SC Wong, K Eloranta, DB Wilson, ... Current Issues in Molecular Biology 44 (2), 686-698, 2022 | 5 | 2022 |
| Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia I Nyholm, M Hukkinen, M Pihlajoki, JR Davidson, A Tyraskis, J Lohi, ... Hepatology 77 (4), 1263-1273, 2023 | 4 | 2023 |
| Neuropilin-2 is associated with increased hepatoblastoma cell viability and motility K Eloranta, R Nousiainen, S Cairo, MP Pakarinen, DB Wilson, M Pihlajoki, ... Frontiers in pediatrics 9, 660482, 2021 | 3 | 2021 |
| UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival R Nousiainen, K Eloranta, N Isoaho, S Cairo, DB Wilson, M Heikinheimo, ... Frontiers in Genetics 14, 1170940, 2023 | 2 | 2023 |
| Biology of childhood hepatoblastoma and the search for novel treatments M Pihlajoki, K Eloranta, R Nousiainen, V Väyrynen, T Soini, A Kyrönlahti, ... Advances in Biological Regulation, 100997, 2023 | 1 | 2023 |
| 54P Targeted treatment options for childhood hepatoblastoma using high-throughput drug screening R Nousiainen, K Eloranta, A Hassinen, J Saarela, S Cairo, V Pietiäinen, ... Annals of Oncology 33, S24, 2022 | 1 | 2022 |
| 171P Immune landscape and CLEVER-1 expression in hepatoblastoma V Väyrynen, K Eloranta, M Pihlajoki, J Lohi, A Kyrönlahti, M Hollmén, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| Hepatoblastooma: kohti entistä parempaa ennustetta K Eloranta, M Pihlajoki, T Soini, J Lohi, J Pesola, J Kanerva, ... | | 2023 |
| Molecular insights into mechanisms of hepatoblastoma pathogenesis K Eloranta Helsingin yliopisto, 2021 | | 2021 |
| Chloroquine inhibits PARP expression in hepatoblastoma M Pihlajoki, K Eloranta, A Kyrönlahti, M Heikinheimo Cancer Research 80 (16_Supplement), 5408-5408, 2020 | | 2020 |
| Transcription Factor GATA4 promotes EMT in Human Hepatoblastoma Cells T Soini, M Pihlajoki, K Eloranta, A Kyronlahti, DB Wilson, M Heikinheimo HEPATOLOGY 66, 645A-645A, 2017 | | 2017 |
| Seerumin FGF19-pitoisuus ennustaa sappitieatresian hoitotuloksia IA Nyholm, M Hukkinen, M Pihlajoki, JR Davidson, A Tyraskis, J Lohi, ... Duodecim, 243, 2013 | | 2013 |
| Kaupungin ja yksityisen sektorin yhteistyö osana uutta paikallista hallintaa-Case Oulun kaupunki K Eloranta | | 2012 |
